Tirzepatide vs Retatrutide
A factual side-by-side from public databases — chemical identity, literature volume, and attributed independent-test coverage. Not a recommendation; we don't rank one above the other.
Tirzepatide is described in the provided sources as a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Multiple phase 3 randomized clinical trials evaluated tirzepatide in adults with obesity (SURMOUNT-1, -4), obesity with type 2 diabetes (SURMOUNT-2), obstructive sleep apnea with obesity (SURMOUNT-OSA), and heart failure with preserved ejection fraction with obesity (SUMMIT).
Retatrutide (LY3437943) is described in the provided sources as a triple receptor agonist targeting glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors, with clinical development studies evaluating it in obesity and related conditions, and in type 2 diabetes. (PMIDs: 37366315, 37385280, 41090431)
| Tirzepatide | Retatrutide | |
|---|---|---|
| Family | GLP-1 & incretin agonists | GLP-1 & incretin agonists |
| Research goals | Metabolic & weight | Metabolic & weight |
| Amino acids | — | — |
| Molecular formula | C225H348N48O68 | — |
| Molecular weight | 4813 g/mol | — |
| CAS number | 2023788-19-2 | — |
| Approx. half-life | — | — |
| Regulatory status | FDA-approved drug | In clinical trials |
| WADA status | — | — |
| Evidence maturity | — | — |
| Research references | 10 | 9 |
| Vendors independently tested | 8 | 20 |
| Best test score (Finnrick) | 0.7 | 8.4 |